×

Year's hottest headed for trouble?

12:32 PM ET Wed, 1 April 2015

Sam Isaly, OrbiMed Advisors managing partner, says valuations are more than they used to be but adds, they're not crazy, they're sensible. He shares his view of the biotech sector.